MGI

MGI Launches DNBSEQ-T20×2 Gene Sequencer

On February 7, MGI launched its Ultra-High Throughput Sequencer DNBSEQ-T20×2, signifying an exciting sub-$100 human genome era.

MGI's CoolMPS™-based products can enter the U.S. Market ten months earlier.

On March 29, the Court in the Northern District of California denied Illumina's request to overturn the jury's decision invalidating the '444 patent, which means MGI has the ability to commercialize the CoolMPS™ technology-based products in the U.S. ten months earlier, by August 2022.

MGI Launches HotMPS High-throughput Sequencing Kit*

On April 27, MGI introduced the new commercial sequencing chemistry, HotMPS*, developed to be used on MGI's DNBSEQ-G400** sequencer and will be available in selected countries from April 2022.

MGI was awarded approximately $334 million

On May 6, the jury in the United States District Court for the District of Delaware ruled that Illumina willfully infringed MGI's Two-color sequencing technology. MGI was awarded approximately $334 million for past damages by Illumina.

MGI Launches its First Magnetic Beads TQ01

In June, MGI Launches its First Magnetic Beads TQ01 to Support Cost-efficient Nucleic Acid Testing.

MGI Announces Commercial Availability of HotMPS Sequencing Chemistry*and Instrument**in the United Kingdom

On July 7, MGI announced that its innovative HotMPS sequencing chemistry* and instrument** are commercially available in the United Kingdom, from 23rd June 2022.

MGI Announces Commercial Availability of DNBSEQ™ Sequencers* in the United States

On Jun 6, MGI announced that its innovative CoolMPS sequencing chemistry and instruments* will become commercially available in the United States beginning from August 29,2022.

MGI reached a settlement agreement in the U.S. with Illumina

On July 15, MGI and its affiliates announced a settlement agreement in the United States with Illumina. Under the terms of the parties' settlement agreement, CGI was awarded a net payment to CGI of $325 Million for past damages by Illumina.

MGI launched its first DNBelab-D4 automated library preparation lab adopting digital microfluidic technology.

On July 23, 2022, MGI launched its first DNBelab-D4 automated library preparation lab adopting digital microfluidic technology at the IDD 2022.

MGI officially launches its DNBSEQ-E25 gene sequencer

On 31 August, 2022, MGI officially launches its DNBSEQ-E25 gene sequencer.

MGI is listed on Shanghai Stock Exchange STAR Market

On 9 September, 2022, MGI is listed on Shanghai Stock Exchange STAR Market (stock symbol: MGI stock, code: 688114).

MGI Launches DNBSEQ-G99 Gene Sequencer

On 19 September 2022, MGI launches ultra-high speed DNBSEQ-G99 gene sequencer* with mid to low range throughput

MGI first introduced its MGISP-NE384 | January 2021

MGISP-NE384 is a high-throughput automated nucleic acid extractor adopting magnetic rod technology.

The opening ceremony of Qingdao Reagent Production Line of MGI is held in MGI Qingdao Base |April, 2021

The opening ceremony marks MGI Qingdao's a solid step forward to a high-end medical health equipment manufacturing hub in Northeast Asia.

MGI DNBelab D series and DNBSEQ-T7 Genetic Sequencer won the iF Design Award | April, 2021

MGI DNBelab D series and DNBSEQ-T7 Genetic Sequencer won the iF Design Award for their innovative functions and exquisite design.

MGI Robotic Ultrasound Vehicle Officially Launched | April, 2021

The platform including remote ultrasound robot, robotic arm and AI diagnosis software, can manage the sample collection and remote real-time diagnosis.

MGI won the 22nd China Patent Awards | June, 2021

MGI won the 22nd China Patent Awards, the top patent awards in China, for its invention patent of “Sample Pretreatment Equipment for Gene Sequencing System”.

MGI Australia Demo Lab Opens to Support APAC Customers | July, 2021

MGI announces the opening of MGI Australia Demonstration Laboratory (Demo Lab) to support the users in Asia-Pacific (APAC).

MGI launches its new DNBSEQ-E5 Genetic Sequencer |July, 2021

MGI launches its new DNBSEQ-E5 Genetic Sequencer for pathogenic microorganism sequencing at the Second Infectious Disease Diagnosis Technology Innovation Forum (IDD) in Wuhan.

MGI Launches All-in-one "Intelligent + Telemedicine" Robotic Ultrasound Platform | September, 2021

This all-in-one platform integrates remote ultrasound robot, handheld ultrasound device, MGI robotic ultrasound vehicle and cloud platform for remote diagnosis to build a new smart healthcare ecosystem

MGI Unveils Performance Upgrades for its Sequencing Platforms and Customized ATOPlex Platform at the ICG-16 | October, 2021

MGI introduced a series of performance upgrades for its gene sequencing platforms and a new multiplex PCR platform at the ICG-16held in Qingdao, China.

MGI Establishes Strategic Alliance with Industry Partners in Cancer Prevention and Treatment | November, 2021

MGI and Roche, together with Aisono and Shanzhen, officially formed a strategic alliance on "Early detection, Early diagnosis, and Early treatment" of Cancer at the 4th China International Import Expo held in Shanghai from 5th to 10th November 2021.

MGI Showcases Latest Laboratory Automation Products at MEDICA 2021 | November, 2021

MGI showcases a selection of its latest laboratory automation technologies for sample transfer, sample extraction, and library preparation at MEDICA 2021 in Messe Düsseldorf, Germany.

MGI ATOPlex Technology Contributes to the Discovery of the First Case of COVID-19 Omicron Variant in Sweden | November, 2021

MGI's proprietary ATOPlex ultra-high multiplex platform provides effective whole-genome sequencing, surveillance, and monitoring of the new Omicron variant in Sweden.

MGI Contributes to Rapid Detection and Surveillance of COVID-19 Omicron Variant | November, 2021

MGI's ATOPlex technology, DNBSEQ-G50 and MGISP-100 supported the detection of omicron in South Africa's wastewater with rapid sequencing and ATOPlex technology.

Hurun report lists 500 most valuable Chinese private companies in 2020, MGI ranked 349 | November 2020

On November 25, 2020, the Hurun Research Institute released its report “Hurun China’s Top 500 Most Valuable Chinese Private Companies 2020". The ranking was based on the market values of Chinese companies from all industries. The Hurun China 500 rose by 55%, to hit US$16bn of value on average, a new record. 436 of the companies on the Hurun list saw their value increase this year, and 120 were new players on the list. Of the 59 companies from Shenzhen, BGI and MGI ranked 178 and 349 respectively.

MGI Named One of the 50 Smartest Companies in 2020 by MIT Technology Review | November 2020

SUZHOU, CHINA, November 19, 2020 – MGI, a global life science technology company, has been selected as one of the 50 smartest companies (TR 50) in China by MIT Technology Review, the world’s oldest technology publication.

MGI Introduces DNBSEQ-T10×4RS Genetic Sequencing System at the ICG-15 | October 2020

WUHAN, CHINA, October 26, 2020 – MGI officially launched its DNBSEQ-T10×4RS Genetic Sequencing System at the 15th International Conference on Genomics (ICG-15) in Wuhan. This solution integrates sample pretreatment, library preparation, high-throughput sequencing, genetic data management, and more. Each sequencing laboratory will be able to achieve an annual throughput of 50,000 to 1 million whole genome sequencing (WGS), with a fully automated process from sample to report.

MGI’s Groundbreaking Ceremony Was as Held in Guanggu, Wuhan! | October 2020

WUHAN, CHINA, October 26, 2020--MGI’s ground-breaking ceremony of “Intelligent Manufacturing and R&D Base" was officially launched in Guanggu Wuhan. The R&D Base is located at Shendun Road 2, East Lake New Technology Development Zone, Wuhan, with an infrastructure investment of 1.264 billion yuan and a total investment of 2.4 billion yuan. The project is expected to complete the first phase in 2022 with a total construction area of 86,000 square meters.

The First Batch of “Huo-Yan” Mobile PCR Lab Were Delivered to Key Medical and Health Institutions in Sichuan | September 2020

CHENGDU, CHINA, September 29, 2020 – four vehicle-mounted nucleic acid testing labs, co-developed by BGI_MGI and Shudu Bus, are ready to launch in Sichun. They are equipped with MGI’s automation equipment and intelligent laboratory management system, and it only takes four persons to achieve a daily throughput of up to 20,000, making them one of the currently most efficient and movable solutions on the market. The Mobile PCR Lab will be officially launched and delivered to key medical and health institutions in Sichuan Province. This means that the “Huo-Yan” Mobile PCR Lab with technical support from MGI will be a powerful support to the epidemic prevention and control in the upcoming fall and winter of this year.

MGI’s Remote Robotic Ultrasound System Won the First Prize in China Medical Device Innovation and Entrepreneurship Competition | September 2020

SUZHOU, CHINA, September 8, 2020 - The Third China Medical Device Innovation and Entrepreneurship Competition was kicked off. The finals of optical-electromechanical products and AI were held in the Suzhou Artificial Intelligence Industrial Park. MGI’s remote robotic ultrasound system, MGIUS-R3 won the “First Prize of Optical-electromechanical Product and AI”.

MGISTP-7000 high-throughput automated sample transfer processing system | August 2020

MGISTP-7000 is our high-throughput automated sample transfer processing system. It integrates tube decapping, tube recapping, barcode identification, automated liquid transfer and negative pressure protection. It decreases steps and delivers the quality and reliability you expect. You can transfer 192 samples from airtight sample tubes or plain tubes to 96-Well Microplates in 40 minutes.

MGISP-NE32 an automated nucleic acid extractor adopting magnetic rod technology | August 2020

MGISP-NE32 is an automated nucleic acid extractor adopting magnetic rod technology. Together with nucleic acid extraction kit, MGISP-NE32 is able to extract and purify nucleic acid from 16/32 samples in approximately 9 mins.

MGI’s Remote Robotic Ultrasound System Receives Approval for Use in China and Europe | May 2020

The world’s first remote robotic ultrasound system, MGIUS-R3, received Class III medical device qualification by the China National Medical Product Administration (NMPA) on May 13, 2020, allowing it to enter the Chinese market and provide state-of-art long-distance ultrasound diagnostic services. MGIUS-R3 was also certified through the EC Full Quality Assurance System in March, which means the product has been approved to enter the EU market.

MGI announced the completion of a $1 billion Series B round of funding | May 2020

On May 28, MGI announced the completion of a $1 billion Series B round of funding. This Series B funding was jointly led by IDG Capital and CPE, with participation by Huaxing New Economic Fund, Shanghai Guofang FoFs, Huatai Zijin Investment, Ti-capital, Sailing-capital, Co-stone, Dingfeng Asset, Guotai Jun’an Innovation Investment, as well as existing investors CITIC Securities/Goldstone, Green Pine Capital Partners and other venture capital firms. This is the second round of large-scale financing completed by MGI after it raised over $200 million in May 2019.

MGIUS-R3 Showed in the Xinwen Lianbo of CCTV | May 2020

On May 20, MGIUS-R3 showed in the Xinwen Lianbo, a daily news program produced by China Central Television (CCTV), a state broadcaster. The news demonstrated that a doctor in Hangzhou is conducting “remote real-time diagnosis” for the patient as far as in Wuhan(the two cities are thousands miles away) by using the remote robotic ultrasound system, MGIUS-R3 with the help of 5G technology.

A new R&D and manufacturing facility in Riga, Latvia | November 2019

In November 2019, MGI officially opened a new R&D and manufacturing facility in Riga, Latvia, aiming to build a bridge between China and Europe for health science innovation and deep experience in the European market and expand its global portfolio.

DNBSEQ E, DNBelab D and DNBelab C series|October 2019

MGI released its new one-stop genome sequencing solution, including the portable "express" sequencing system DNBSEQ E series, the modular "digital biolab" DNBelab D series for use with the sequencing system, and a new single "cell" DNBelab C series, a handheld single-cell laboratory that can fit into a pocket.

The Global Sequencer User Program released|January 2019

The Global Sequencer User Program was released at the 37th Annual J.P. Morgan Healthcare Conference to promote collaborative innovation and development of the industry through the sharing of sequencing platforms and technologies.

MGISP-100 Automated Sample Preparation System Receives Certification as Class II Medical Device | April 2019

MGI's new automated sample preparation, the first one-stop gene sequencing preparation system in China to receive the certification.

Ultra-high-throughput sequencer, DNBSEQ-T7 (initially named MGISEQ-T7)| October 2018

Launched ultra-high-throughput sequencer, DNBSEQ-T7 (initially named MGISEQ-T7), the most powerful sequencer to date, and the high-throughput automated sample preparation system MGISP-960.Launched the new library preparation kit for single tube Long Fragment Reads (stLFR) technology.

High-throughput Automated Sample Preparation System MGISP-960 | October 2018

MGISP-960 high-throughput automated sample preparation system with built-in routine NGS database construction process and fully automated operation, can process 8-96 samples at one time and can be customized according to customer needs. It is a flexible with a wide usage range of automated samples preparation system.

Launch MegaBOLT bioinformatics analysis accelerator | May 2018

MegaBOLT adopts the heterogeneous computing system of CPU and FPGA, which greatly improves the analysis speed. It shortens the 100 Gbp WGS analysis duration to 2 hours and 6 Gbp WES analysis duration to 10 minutes.

Win iF Design Award | Feb 2018

BGISEQ-50 and MGIUS-R3 independently developed by MGI won two awards of iF Design Award in Germany for their breakthrough function and exquisite design in February 2018.

DNBSEQ-G400，DNBSEQ-G50，MGIFLP，MGIUS-R3 | Oct 2017

Remark: DNBSEQ-G400 and DNBSEQ-G50 remain their original product names as MGISEQ-2000 and MGISEQ-200 respectively in China and some other overseas countries. Two new sequencers for more power and lower cost, as well as a highly integrated modular NGS workstation and a remote robotic ultrasound system for exploring more possibility of the future.

Circulating tumor cell separator (CTC) | Sep 2017

Technology and intelligence come together perfectly in this epoch-making clinical trial that enhances the separation and enrichment efficiency by as much as 100,000 times, with a user-oriented, fully-automated, real-time smart cell-seeking technology. The tumor has nowhere to hide

ISO 13485 | July 2017

MGI obtained the 13485 medical device quality management system certification.

Mobile Medical Vehicle | April 2017

The launch of mobile medical vehicles provided a solid guarantee for the screening of echinococcosis in remote areas of China.

The BGISEQ-50 high-throughput desktop sequencing system | Nov 2016

Broad array of applications with no constraints in terms of space. Suitable for use at low-pressure, high-altitude environments. Multiple integrated functions are enclosed within its compact and simple structure, and its small footprint makes for easy placement.

BGISEQ-500n Total Solution | May 2016

BGISEQ-500n aims at different sequencing application needs, and optimizes the configuration of various BGISEQ-500 to build flexiblely large, medium and small sequencing platforms. It also strives to provide the most efficient and convenient solution forscientific researchers.

The BGISEQ-500 high-throughput desktop sequencing system | Oct 2015

MGI Tech has complete ownership of intellectual property rights to the device. It can satisfy all clinical needs, and at full speed, can complete the entire sequencing process within 24 hours. BGISEQ-500 has received CFDA and CE approval successively. Supports the development of precise medicine and brings the benefits of gene technology to the people.

The Revolocity sequencing system | June 2015

The Revolocity is a fully-integrated "super sequencer", with its first users being Mater, a health services provider in Australia, and the Nijmegen University Medical Center in the Netherlands.

The BGISEQ-1000 sequencing system | July 2014

The system was approved by the State Food and Drug Administration in 2014, and this development generated much market buzz for related stocks.

Successful acquisition of U.S. company Complete Genomics | March 2013

Intense industry competition made us even more determined to acquire the listed company Complete Genomics. We have been able to reduce costs right from the inception stage by utilizing CG's cutting-edge biotechnologies and instrument technologies.